Learn/Cannabinoids

Cannabinoids

Cannabis contains over 100 identified cannabinoids. This guide covers the most clinically relevant compounds — their mechanisms of action, what the research shows, and what it means for consumers and patients.

The Endocannabinoid System

Cannabinoids work by interacting with the body's endocannabinoid system (ECS) — a regulatory network of receptors (CB1, CB2), endogenous ligands (anandamide, 2-AG), and enzymes present throughout the brain, immune system, and peripheral tissues.

The ECS plays a role in regulating pain, mood, appetite, memory, immune function, and sleep. Understanding it is foundational to understanding how cannabinoids produce their effects.

Evidence Grades:Grade A — Strong EvidenceGrade B — Moderate EvidenceGrade C — Emerging Evidence

Primary Cannabinoids

The most studied and clinically relevant compounds.

CBD

Cannabidiol

Grade A

The most studied non-psychoactive cannabinoid. FDA-approved (Epidiolex) for treatment-resistant epilepsy. Strong evidence for anxiety reduction; moderate evidence for pain and inflammation.

Mechanism

Indirect modulation of CB1/CB2 receptors; serotonin 5-HT1A agonist; TRPV1 modulation.

EpilepsyAnxietyInflammationPain

Full Profile

THCPsychoactive

Tetrahydrocannabinol

Grade A

The primary psychoactive cannabinoid. FDA-approved derivatives (dronabinol, nabilone) for chemotherapy-induced nausea and AIDS-related anorexia. Strong evidence for pain and spasticity.

Mechanism

Partial agonist at CB1 and CB2 receptors. CB1 activation produces psychoactive effects.

PainNauseaAppetiteSpasticity

Full Profile

Minor Cannabinoids

Emerging compounds with growing research interest.

CBGGrade C

Cannabigerol

The "mother cannabinoid" — a precursor to CBD and THC. Emerging preclinical evidence for neuroprotection and anti-inflammatory effects. Human trials are limited.

InflammationNeuroprotectionAntibacterial

Full Profile

CBNGrade C

Cannabinol

A degradation product of THC with mild psychoactive properties. Commonly marketed for sleep, though clinical evidence is currently limited. Ongoing trials are underway.

SleepSedationPain

Full Profile

CBCGrade C

Cannabichromene

A non-psychoactive cannabinoid with preclinical evidence for anti-inflammatory and analgesic effects. May promote neurogenesis. Human data is scarce.

InflammationPainNeurogenesis

Full Profile

THCVGrade C

Tetrahydrocannabivarin

A structural analog of THC with distinct effects — may suppress appetite (opposite of THC) and shows early promise for type 2 diabetes management. Psychoactive at high doses.

Appetite SuppressionBlood SugarBone Growth

Full Profile

CBDAGrade C

Cannabidiolic Acid

The raw, unheated precursor to CBD found in fresh cannabis. Emerging research suggests CBDA may be more potent than CBD for nausea and anxiety via 5-HT1A agonism. Converts to CBD when heated.

NauseaAnxietyInflammation

Full Profile

THCAGrade C

Tetrahydrocannabinolic Acid

The dominant cannabinoid in raw, unheated cannabis — non-psychoactive until decarboxylated to THC by heat. Preclinical evidence for neuroprotection via PPARγ agonism. "THCA flower" products carry intoxication risk.

NeuroprotectionInflammationNausea

Full Profile

Δ8-THCGrade C

Delta-8-THC

A mildly psychoactive THC isomer (~50–66% potency of Delta-9-THC). One clinical study showed anti-nausea efficacy in pediatric oncology patients. Most commercial products are synthetically derived from CBD with significant safety concerns.

NauseaAnxietyPain

Full Profile

Δ10-THCGrade C

Delta-10-THC

A trace THC isomer primarily produced synthetically from CBD. Reported to produce milder, more stimulating effects than Delta-9-THC. Extremely limited research — no human clinical trials. Significant safety concerns about synthesis byproducts.

No established uses

Full Profile

Explore the Research Behind These Compounds

Our Research Library contains clinical study summaries with evidence grading, organized by cannabinoid and condition.

Research Library